Arcutis Biotherapeutics: Resilient Performance and Growth Potential Amidst Short-Term Fluctuations

TipRanksNov 25 15:36

Bears Are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Zacks Nov 19 22:05

Arcutis' ZORYVE (Roflumilast) Awarded Best Eczema Treatment by Glamour

Arcutis BiotherapeuticsNov 13 21:00

Express News | Arcutis Biotherapeutics Inc : Guggenheim Raises Target Price to $29 From $27

BreakingsNov 8 20:28

Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18

Futu NewsNov 7 20:31 · Ratings

Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19

Futu NewsNov 7 19:33 · Ratings